Shots: Suzhou Alphamab to receive up front & will be eligible to receive development, regulatory & commercial milestones along with royalties & will manufacture ASC22 for clinical trials & commercialization […]readmore
Tags : Hepatitis B
Shots: Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989, JNJ-6379, […]readmore
Shots: Durect to receive $25M up front, ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW […]readmore